Skip to main content
. 2016 Jun 9;23(11):3510–3517. doi: 10.1245/s10434-016-5296-y

Fig. 2.

Fig. 2

Ratings of likelihood that a patient will be referred for NST, by disease factor. ER estrogen receptor, HER2 human epidermal growth factor receptor 2, IBC inflammatory breast cancer, NST neoadjuvant systemic therapy, PR progesterone receptor. Note Each respondent rated only the five characteristics that he or she associated the most with aggressiveness of disease